Publikationen

Medizin 1

Direktor:
Prof. Dr. med. Markus F. Neurath

Arbeitsgruppe Patientenorientierte Forschung und innovative Therapiestrategien bei chronisch entzündlichen Darmerkrankungen

Publikationen

Auswahl der wichtigsten Publikationen

Atreya R., Neurath MF. (2018) Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease. Lancet Gastroenterol Hepatol. Nov;3:790-802.

Schmitt H, Billmeier U, Dieterich W, Rath T, Sonnewald S, Reid S, Hirschmann S, Hildner K, Waldner MJ, Mudter J, Hartmann A, Grützmann R, Neufert C, Münster T, Neurath MF, Atreya R. (2018) Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease. Gut. May 30.

Rath T, Billmeier U, Ferrazzi F, Vieth M, Ekici A, Neurath MF, Atreya R. (2018) Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases. Front Immunol. Jul 31;9:1700.

Atreya R, Siegmund B. (2018) IBD in 2017: Development of therapy for and prediction of IBD - getting personal. Nat Rev Gastroenterol Hepatol. Feb;15:72-74.

Rath T, Bojarski C, Neurath MF, Atreya R. (2017) Molecular imaging of mucosal α4β7 integrin expression with the fluorescent anti-adhesion antibody vedolizumab in Crohn's disease. Gastrointest Endosc. 86, 406-08.

Atreya R, Bloom S, Scaldaferri F, Gerardi V, Admyre C, Karlsson Å, Knittel T, Kowalski J, Lukas M, Löfberg R, Nancey S, Petryka R, Rydzewska G, Schnabel R, Seidler U, Neurath MF, Hawkey C. (2016). Clinical effects of a topically applied Toll-like receptor 9 agonist in active moderate-to-severe Ulcerative Colitis. J Crohns Colitis. 10,1294-1302.

Hess A, Roesch J, Saake M, Sergeeva M, Hirschmann S, Neumann H, Dörfler A, Neurath MF, Atreya R. (2015). Functional Brain Imaging Reveals Rapid Blockade of Abdominal Pain Response Upon Anti-TNF Therapy in Crohn's Disease. Gastroenterology. 149,864-6.

Atreya R, Neumann H, Neufert C, Waldner MJ, Billmeier U, Zopf Y, Willma M, App C, Münste T, Kessler H, Maas S, Gebhardt B, Heimke-Brinck R, Reuter E, Dörje F, Rau TT, Uter W, Wang TD, Kiesslich R, Vieth M, Hannappel E, Neurath MF. (2014). In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. Nat Med. 20,313-8.

Atreya, R, Zimmer M, Bartsch B, Waldner MJ, Atreya I, Neumann H, Hildner K, Hoffman A, Kiesslich R, Rink AD, Rau TT, Rose-John S, Kessler H, Schmidt J, Neurath MF. (2011). Antibodies Against Tumor Necrosis Factor (TNF) Induce T-Cell Apoptosis in Patients With Inflammatory Bowel Diseases via TNF Receptor 2 and Intestinal CD14+ Macrophages. Gastroenterology. 141,2026-38.

Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schürmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF. (2000) Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med. 6,583-8.

Publikationsliste (in Pubmed gelisted)

h-index: 28      Zitationen (gesamt): 4664 (Source: SCOPUS 02.11.2018)

1.    Scheibe K, Kersten C, Schmied A, Vieth M, Primbs T, Carlé B, Knieling F, Claussen J, Klimowicz AC, Zheng J, Baum P, Meyer S, Schürmann S, Friedrich O, Waldner MJ, Rath T, Wirtz S, Kollias G, Ekici AB, Atreya R, Raymond EL, Mbow ML, Neurath MF, Neufert C. Inhibiting Interleukin 36 Receptor Signaling Reduces Fibrosis in Mice with Chronic Intestinal Inflammation. Gastroenterology. 2018 Nov 16.

2.    Brunner M, Agaimy A, Atreya R, Grützmann R, Matzel KE. Cap polyposis in children: case report and literature review. Int J Colorectal Dis. 2018 Nov 13.

3.    Klenske E, Osaba L, Nagore D, Rath T, Neurath MF, Atreya R. Drug Levels in the Maternal Serum, Cord Blood and Breast Milk of a Ustekinumab-Treated Patient with  Crohn's Disease. J Crohns Colitis. 2018 Nov 2.

4.    Atreya R, Neurath MF. Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2018 Nov;3(11):790-802.

5.    Zundler S, Dietz L, Matzel KE, Geppert CI, Becker E, Rath T, Neurath MF, Atreya R. Successful Long-term Treatment of Diversion Colitis with Topical Coconut Oil Application. Am J Gastroenterol. 2018 Oct 23.

6.    Authors; Collaborators: [Updated S3-Guideline Colitis ulcerosa. German Society for Digestive and Metabolic Diseases (DGVS) - AWMF Registry 021/009]. Z Gastroenterol. 2018 Sep;56(9):1087-1169.

7.    Rath T, Billmeier U, Ferrazzi F, Vieth M, Ekici A, Neurath MF, Atreya R. Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases. Front Immunol. 2018 Jul 31;9:1700.

8.    Atreya R, Reinisch W, Peyrin-Biroulet L, Scaldaferri F, Admyre C, Knittel T, Kowalski J, Neurath MF, Hawkey C. Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis. Dig Liver Dis. 2018 Oct;50(10):1019-1029.

9.    Rath T, Kiesslich R, Neurath MF, Atreya R. Molecular imaging within the lower  gastrointestinal tract: From feasibility to future. Dig Endosc. 2018 Aug 3.

10.   Simon D, Kleyer A, Englbrecht M, Stemmler F, Simon C, Berlin A, Kocijan R, Haschka J, Hirschmann S, Atreya R, Neurath MF, Sticherling M, Rech J, Hueber AJ,  Engelke K, Schett G. A comparative analysis of articular bone in large cohort of patients with chronic inflammatory diseases of the joints, the gut and the skin.  Bone. 2018 Nov;116:87-93.

11.   Klenske E, Neurath MF, Atreya R, Rath T. Molecular imaging in gastroenterology: A route for personalized endoscopy. Dig Liver Dis. 2018 Sep;50(9):878-885.

12.   Schmitt H, Billmeier U, Dieterich W, Rath T, Sonnewald S, Reid S, Hirschmann S, Hildner K, Waldner MJ, Mudter J, Hartmann A, Grützmann R, Neufert C, Münster T, Neurath MF, Atreya R. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease. Gut. 2018 May 30.

13.   Binder MT, Becker E, Wiendl M, Schleier L, Fuchs F, Leppkes M, Atreya R, Neufert C, Atreya I, Neurath MF, Zundler S. Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s. Inflamm Bowel Dis. 2018 May 18;24(6):1237-1250.

14.   Koelink PJ, Wildenberg ME, Stitt LW, Feagan BG, Koldijk M, van 't Wout AB, Atreya R, Vieth M, Brandse JF, Duijst S, Te Velde AA, D'Haens GRAM, Levesque BG,  van den Brink GR. Development of Reliable, Valid and Responsive Scoring Systems for Endoscopy and Histology in Animal Models for Inflammatory Bowel Disease. J Crohns Colitis. 2018 Jun 28;12(7):794-803.

15.   Goertz RS, Klett D, Wildner D, Atreya R, Neurath MF, Strobel D. Quantitative contrast-enhanced ultrasound for monitoring vedolizumab therapy in inflammatory bowel disease patients: a pilot study. Acta Radiol. 2018 Oct;59(10):1149-1156.

16.   Atreya R, Siegmund B. IBD in 2017: Development of therapy for and prediction of IBD - getting personal. Nat Rev Gastroenterol Hepatol. 2018 Feb;15(2):72-74. 2017

17.   Wiesinger M, Stoica D, Roessner S, Lorenz C, Fischer A, Atreya R, Neufert CF, Atreya I, Scheffold A, Schuler-Thurner B, Neurath MF, Schuler G, Voskens CJ. Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders. Front Immunol. 2017 Oct 26;8:1371.

18.   Rath T, Atreya R, Geißdörfer W, Lang R, Nägel A, Neurath MF. A Severe Case of Tuberculosis Radiologically and Endoscopically Mimicking Colorectal Cancer with Peritoneal Carcinomatosis. Case Rep Gastrointest Med. 2017;2017:6206951.

19.   Tontini GE, Mudter J, Vieth M, Günther C, Milani V, Atreya R, Rath T, Nägel A, Hatem G, Sturniolo GC, Vecchi M, Neurath MF, Galle PR, Buda A, Neumann H. Prediction of clinical outcomes in Crohn's disease by using confocal laser endomicroscopy: results from a prospective multicenter study. Gastrointest Endosc. 2018 Jun;87(6):1505-1514.e3.

20.   Waldner MJ, Rath T, Schürmann S, Bojarski C, Atreya R. Imaging of Mucosal Inflammation: Current Technological Developments, Clinical Implications, and Future Perspectives. Front Immunol. 2017 Oct 11;8:1256.

21.   Fischer S, Rath T, Geppert CI, Manger B, Schett G, Neurath MF, Atreya R. Long-term Combination Therapy with Anti-TNF plus Vedolizumab Induces and Maintains Remission in Therapy-refractory Ulcerative Colitis. Am J Gastroenterol. 2017 Oct;112(10):1621-1623.

22.   Fuchs F, Schillinger D, Atreya R, Hirschmann S, Fischer S, Neufert C, Atreya  I, Neurath MF, Zundler S. Clinical Response to Vedolizumab in Ulcerative Colitis  Patients Is Associated with Changes in Integrin Expression Profiles. Front Immunol. 2017 Jul 3;8:764.

23.   Voskens CJ, Fischer A, Roessner S, Lorenz C, Hirschmann S, Atreya R, Neufert  C, Atreya I, Neurath MF, Schuler G. Characterization and Expansion of Autologous  GMP-ready Regulatory T Cells for TREG-based Cell Therapy in Patients with Ulcerative Colitis. Inflamm Bowel Dis. 2017 Aug;23(8):1348-1359.

24.   Atreya R, Neurath MF. Current and Future Targets for Mucosal Healing in Inflammatory Bowel Disease. Visc Med. 2017 Mar;33(1):82-88.

25.   Hirschmann S, Atreya R, Englbrecht M, Neurath MF. Safety and efficacy of intravenous cyclophosphamide pulse therapy in therapy refractory Crohn's disease patients. J Physiol Pharmacol. 2017 Feb;68(1):57-67.

26.   Knieling F, Neufert C, Hartmann A, Claussen J, Urich A, Egger C, Vetter M, Fischer S, Pfeifer L, Hagel A, Kielisch C, Görtz RS, Wildner D, Engel M, Röther J, Uter W, Siebler J, Atreya R, Rascher W, Strobel D, Neurath MF, Waldner MJ. Multispectral Optoacoustic Tomography for Assessment of Crohn's Disease Activity. N Engl J Med. 2017 Mar 30;376(13):1292-1294.

27.   Chiriac MT, Buchen B, Wandersee A, Hundorfean G, Günther C, Bourjau Y, Doyle  SE, Frey B, Ekici AB, Büttner C, Weigmann B, Atreya R, Wirtz S, Becker C, Siebler J, Neurath MF. Activation of Epithelial Signal Transducer and Activator of Transcription 1 by Interleukin 28 Controls Mucosal Healing in Mice With Colitis and Is Increased in Mucosa of Patients With Inflammatory Bowel Disease. Gastroenterology. 2017 Jul;153(1):123-138.e8.

28.   Vetter M, Neurath MF, Atreya R. [Crohn's disease - use of biomarkers in general practice]. MMW Fortschr Med. 2017 Feb;159(3):63-68.

29.   Zundler S, Fischer A, Schillinger D, Binder MT, Atreya R, Rath T, Lopez-Pósadas R, Voskens CJ, Watson A, Atreya I, Neufert C, Neurath MF. The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells  In Vivo. Inflamm Bowel Dis. 2017 Mar;23(3):379-391.

30.   Rath T, Bojarski C, Neurath MF, Atreya R. Molecular imaging of mucosal α4β7 integrin expression with the fluorescent anti-adhesion antibody vedolizumab in Crohn's disease. Gastrointest Endosc. 2017 Aug;86(2):406-408.

31.   Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI–IM-UNITI Study Group. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016 Nov 17;375(20):1946-1960.

32.   Atreya R, Neurath MF. [Novel therapeutic approaches in inflammatory bowel diseases]. Dtsch Med Wochenschr. 2016 Nov;141(24):1789-1792. Epub 2016 Nov 30.

33.   Billmeier U, Dieterich W, Neurath MF, Atreya R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J  Gastroenterol. 2016 Nov 14;22(42):9300-9313.

34.   Atreya R, Neurath MF. Endoscopy: Chromoendoscopy in IBD: indispensable in real-life screening. Nat Rev Gastroenterol Hepatol. 2016 Dec;13(12):688-690.

35.   Atreya R, Bloom S, Scaldaferri F, Gerardi V, Admyre C, Karlsson Å, Knittel T, Kowalski J, Lukas M, Löfberg R, Nancey S, Petryka R, Rydzewska G, Schnabel R, Seidler U, Neurath MF, Hawkey C. Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis. J Crohns Colitis. 2016 Nov;10(11):1294-1302.

36.   Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, Hampe J, Hartmann F, Neurath MF, Maul J, Preiss JC, Schmelz R, Siegmund B, Schulze H, Teich N, von Arnim U, Baumgart DC, Schmidt C. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease – a prospective multicenter observational study. Aliment Pharmacol Ther. 2016 Dec;44(11-12):1199-1212.

37.   Siegmund B, Atreya R, Bokemeyer B, Kruis W, Mudter J, Sander C, Schreiber S,  Reindl W, Zeissig S, Kucharzik T. [Biosimilars in inflammatory bowel disease]. Z Gastroenterol. 2016 Nov;54(11):1217-1222.

38.   Popp V, Gerlach K, Mott S, Turowska A, Garn H, Atreya R, Lehr HA, Ho IC, Renz H, Weigmann B, Neurath MF. Rectal Delivery of a DNAzyme That Specifically Blocks  the Transcription Factor GATA3 and Reduces Colitis in Mice. Gastroenterology. 2017 Jan;152(1):176-192.e5.

39.   Zundler S, Schillinger D, Fischer A, Atreya R, López-Posadas R, Watson A, Neufert C, Atreya I, Neurath MF. Blockade of αEβ7 integrin suppresses accumulation of CD8(+) and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo. Gut. 2017 Nov;66(11):1936-1948.

40.   Rau TT, Atreya R, Aust D, Baretton G, Eck M, Erlenbach-Wünsch K, Hartmann A,  Lugli A, Stöhr R, Vieth M, Wirsing AM, Zlobec I, Katzenberger T. Inflammatory response in serrated precursor lesions of the colon classified according to WHO entities, clinical parameters and phenotype-genotype correlation. J Pathol Clin Res. 2016 Feb 25;2(2):113-24.

41.   Suzuki K, Yokoyama J, Kawauchi Y, Honda Y, Sato H, Aoyagi Y, Terai S, Okazaki K, Suzuki Y, Sameshima Y, Fukushima T, Sugahara K, Atreya R, Neurath MF, Watanabe K, Yoneyama H, Asakura H. Phase 1 Clinical Study of siRNA Targeting Carbohydrate  Sulphotransferase 15 in Crohn's Disease Patients with Active Mucosal Lesions. J Crohns Colitis. 2017 Feb;11(2):221-228.

42.   Suzuki K, Arumugam S, Yokoyama J, Kawauchi Y, Honda Y, Sato H, Aoyagi Y, Terai S, Okazaki K, Suzuki Y, Mizumoto S, Sugahara K, Atreya R, Neurath MF, Watanabe K, Hashiguchi T, Yoneyama H, Asakura H. Pivotal Role of Carbohydrate Sulfotransferase 15 in Fibrosis and Mucosal Healing in Mouse Colitis. PLoS One. 2016 Jul 13;11(7):e0158967.

43.   Chernavskaia O, Heuke S, Vieth M, Friedrich O, Schürmann S, Atreya R, Stallmach A, Neurath MF, Waldner M, Petersen I, Schmitt M, Bocklitz T, Popp J. Beyond endoscopic assessment in inflammatory bowel disease: real-time histology of disease activity by non-linear multimodal imaging. Sci Rep. 2016 Jul 13;6:29239.

44.   Atreya R, Neurath MF. Predicting Therapeutic Response by in vivo Molecular Imaging in Inflammatory Bowel Diseases. Dig Dis. 2016;34(5):552-7.

45.   Waldner MJ, Knieling F, Egger C, Morscher S, Claussen J, Vetter M, Kielisch C, Fischer S, Pfeifer L, Hagel A, Goertz RS, Wildner D, Atreya R, Strobel D, Neurath MF. Multispectral Optoacoustic Tomography in Crohn's Disease: Noninvasive Imaging of Disease Activity. Gastroenterology. 2016 Aug;151(2):238-40.

46.   Fischer S, Neurath MF, Atreya R. [Colitis ulcerosa - a diagnostic and therapeutic update]. MMW Fortschr Med. 2016 Apr 28;158(8):77-80.

47.   Atreya R, Neurath MF. From bench to bedside: molecular imaging in inflammatory bowel diseases. Curr Opin Gastroenterol. 2016 Jul;32(4):245-50.

48.   Atreya I, Diall A, Dvorsky R, Atreya R, Henninger C, Grün M, Hofmann U, Schaeffeler E, López-Posadas R, Daehn I, Zenker S, Döbrönti M, Neufert C, Billmeier U, Zundler S, Fritz G, Schwab M, Neurath MF. Designer Thiopurine-analogues for Optimised Immunosuppression in Inflammatory Bowel Diseases. J Crohns Colitis. 2016 Oct;10(10):1132-43.

49.   Baumgart DC, Bokemeyer B, Drabik A, Stallmach A, Schreiber S; Vedolizumab Germany Consortium. Vedolizumab induction therapy for inflammatory bowel disease  in clinical practice--a nationwide consecutive German cohort study. Aliment Pharmacol Ther. 2016 May;43(10):1090-102.

50.   Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, Plevy S, Popp  J, Cornillie FJ, Lukas M, Danese S, Gionchetti P, Hanauer SB, Reinisch W, Sandborn WJ, Sorrentino D, Rutgeerts P; PREVENT Study Group. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology. 2016 Jun;150(7):1568-1578.

51.   Haschka J, Hirschmann S, Kleyer A, Englbrecht M, Faustini F, Simon D, Figueiredo CP, Schuster L, Muschitz C, Kocijan R, Resch H, Atreya R, Rech J, Neurath MF, Schett G. High-resolution Quantitative Computed Tomography Demonstrates Structural Defects in Cortical and Trabecular Bone in IBD Patients. J Crohns Colitis. 2016 May;10(5):532-40.

52.   Schey R, Dornhoff H, Baier JL, Purtak M, Opoka R, Koller AK, Atreya R, Rau TT, Daniel C, Amann K, Bogdan C, Mattner J. CD101 inhibits the expansion of colitogenic T cells. Mucosal Immunol. 2016 Sep;9(5):1205-17.

53.   López-Posadas R, Becker C, Günther C, Tenzer S, Amann K, Billmeier U, Atreya  R, Fiorino G, Vetrano S, Danese S, Ekici AB, Wirtz S, Thonn V, Watson AJ, Brakebusch C, Bergö M, Neurath MF, Atreya I. Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation. J Clin Invest. 2016 Feb;126(2):611-26.

54.   Atreya R, Billmeier U, Rath T, Mudter J, Vieth M, Neumann H, Neurath MF. First case report of exacerbated ulcerative colitis after anti-interleukin-6R salvage therapy. World J Gastroenterol. 2015 Dec 7;21(45):12963-9.

55.   Atreya R, Neumann H, Neurath MF. [Update: chronic inflammatory bowel disease]. Dtsch Med Wochenschr. 2015 Nov;140(23):1762-72.

56.   Lamprecht G, Atreya R, Kreis ME, Siegmund B, Stallmach A. Inflammatory Bowel  Diseases: Current Medical and Surgical Therapy. Viszeralmedizin. 2015 Aug;31(4):287-9.

57.   Neumann H, Neurath MF, Atreya R. Endoscopic Therapy in Inflammatory Bowel Diseases. Viszeralmedizin. 2015 Aug;31(4):280-6.

58.   Teich N, Mohl W, Bokemeyer B, Bündgens B, Büning J, Miehlke S, Hüppe D, Maaser C, Klugmann T, Kruis W, Siegmund B, Helwig U, Weismüller J, Drabik A, Stallmach A; German IBD Study Group. Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases--A Prospective Study on Incidence and Severity. J Crohns Colitis. 2016 Jan;10(1):61-8.

59.   Hess A, Roesch J, Saake M, Sergeeva M, Hirschmann S, Neumann H, Dörfler A, Neurath MF, Atreya R. Functional Brain Imaging Reveals Rapid Blockade of Abdominal Pain Response Upon Anti-TNF Therapy in Crohn's Disease. Gastroenterology. 2015 Oct;149(4):864-6.

60.   Fischer A, Zundler S, Atreya R, Rath T, Voskens C, Hirschmann S, López-Posadas R, Watson A, Becker C, Schuler G, Neufert C, Atreya I, Neurath MF.  Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. Gut. 2016 Oct;65(10):1642-64.

61.   Neumann H, Neurath MF, Atreya R. [Endoscopic therapies in inflammatory bowel  diseases]. MMW Fortschr Med. 2015 Jun;157(12):63-6.

62.   Srinivasan B, Focke-Tejkl M, Weber M, Pahr S, Baar A, Atreya R, Neurath MF, Vogelsang H, Huber WD, Valenta R. Usefulness of recombinant γ-gliadin 1 for identifying patients with celiac disease and monitoring adherence to a gluten-free diet. J Allergy Clin Immunol. 2015 Dec;136(6):1607-1618.e3.

63.   Punkenburg E, Vogler T, Büttner M, Amann K, Waldner M, Atreya R, Abendroth B, Mudter J, Merkel S, Gallmeier E, Rose-John S, Neurath MF, Hildner K. Batf-dependent Th17 cells critically regulate IL-23 driven colitis-associated colon cancer. Gut. 2016 Jul;65(7):1139-50.

64.   Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F, Scribano ML, Armuzzi A, Caprioli F, Sturniolo GC, Rogai F, Vecchi M, Atreya R, Bossa F, Onali S, Fichera M, Corazza GR, Biancone L, Savarino V, Pica R, Orlando  A, Pallone F. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med. 2015 Mar 19;372(12):1104-13.

65.   Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol. 2015 Apr;89(4):541-54.

66.   Tontini GE, Mudter J, Vieth M, Atreya R, Günther C, Zopf Y, Wildner D, Kiesslich R, Vecchi M, Neurath MF, Neumann H. Confocal laser endomicroscopy for the differential diagnosis of ulcerative colitis and Crohn's disease: a pilot study. Endoscopy. 2015 May;47(5):437-43.

67.   Atreya R, Neurath MF. IBD pathogenesis in 2014: Molecular pathways controlling barrier function in IBD. Nat Rev Gastroenterol Hepatol. 2015 Feb;12(2):67-8.

68.   Atreya R, Neurath MF. Novel imaging modalities for immune cell monitoring in  the intestine. Curr Opin Gastroenterol. 2014 Nov;30(6):553-8.

69.   Steiner S, Daniel C, Fischer A, Atreya I, Hirschmann S, Waldner M, Neumann H, Neurath M, Atreya R, Weigmann B. Cyclosporine A regulates pro-inflammatory cytokine production in ulcerative colitis. Arch Immunol Ther Exp (Warsz). 2015 Feb;63(1):53-63.

70.   Atreya R, Bülte M, Gerlach GF, Goethe R, Hornef MW, Köhler H, Meens J, Möbius P, Roeb E, Weiss S; ZooMAP Consortium. Facts, myths and hypotheses on the zoonotic nature of Mycobacterium avium subspecies paratuberculosis. Int J Med Microbiol. 2014 Oct;304(7):858-67.

71.   Albrecht H, Naegel A, Hagel A, Roesler W, Foertsch T, Neurath MF, Atreya R, Raithel M. Over-the-scope-clipping in colonic perforation caused small-bowel fixation and pneumoperitoneum requiring surgical repair. Endoscopy. 2014;46 Suppl 1 UCTN:E314-5.

72.   Eftekhari P, Glaubitz L, Breidert M, Neurath MF, Atreya R. Physiological intermolecular modification spectroscopy for the prediction of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel diseases. Dig Dis. 2014;32(4):446-54.

73.   Nalleweg N, Chiriac MT, Podstawa E, Lehmann C, Rau TT, Atreya R, Krauss E, Hundorfean G, Fichtner-Feigl S, Hartmann A, Becker C, Mudter J. IL-9 and ist receptor are predominantly involved in the pathogenesis of UC. Gut. 2015 May;64(5):743-55.

74.   Gerlach K, Hwang Y, Nikolaev A, Atreya R, Dornhoff H, Steiner S, Lehr HA, Wirtz S, Vieth M, Waisman A, Rosenbauer F, McKenzie AN, Weigmann B, Neurath MF. TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol.  2014 Jul;15(7):676-86.

75.   Atreya R, Neumann H, Neufert C, Waldner MJ, Billmeier U, Zopf Y, Willma M, App C, Münster T, Kessler H, Maas S, Gebhardt B, Heimke-Brinck R, Reuter E, Dörje F, Rau TT, Uter W, Wang TD, Kiesslich R, Vieth M, Hannappel E, Neurath MF. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. Nat Med. 2014 Mar;20(3):313-8.

76.   Atreya R, Goetz M. Molecular imaging in gastroenterology. Nat Rev Gastroenterol Hepatol. 2013 Dec;10(12):704-12.

77.   Schürmann S, Foersch S, Atreya R, Neumann H, Friedrich O, Neurath MF, Waldner MJ. Label-free imaging of inflammatory bowel disease using multiphoton microscopy. Gastroenterology. 2013 Sep;145(3):514-6.

78.   Neumann H, Vieth M, Günther C, Neufert C, Kiesslich R, Grauer M, Atreya R, Neurath MF. Virtual chromoendoscopy for prediction of severity and disease extent in patients with inflammatory bowel disease: a randomized controlled study. Inflamm Bowel Dis. 2013 Aug;19(9):1935-42.

79.   Atreya R, Neumann H, Neurath MF. [Rational treatment of Crohn's disease]. MMW Fortschr Med. 2013 Mar 7;155(4):61-3.

80.   Neumann H, Vieth M, Fry LC, Günther C, Atreya R, Neurath MF, Mönkemüller K. Learning curve of virtual chromoendoscopy for the prediction of hyperplastic and  adenomatous colorectal lesions: a prospective 2-center study. Gastrointest Endosc. 2013 Jul;78(1):115-20.

81.   Neumann H, Günther C, Vieth M, Grauer M, Wittkopf N, Mudter J, Becker C, Schoerner C, Atreya R, Neurath MF. Confocal laser endomicroscopy for in vivo diagnosis of Clostridium difficile associated colitis - a pilot study. PLoS One. 2013;8(3):e58753.

82.   Atreya R, Neumann H, Neurath MF. [Rational treatment of ulcerative colitis--local or systemic therapy? Surgery?]. MMW Fortschr Med. 2012 Jul 26;154(13):76-8.

83.   Gerlach K, Daniel C, Lehr HA, Nikolaev A, Gerlach T, Atreya R, Rose-John S, Neurath MF, Weigmann B. Transcription factor NFATc2 controls the emergence of colon cancer associated with IL-6-dependent colitis. Cancer Res. 2012 Sep 1;72(17):4340-50.

84.   Neumann H, Vieth M, Neurath MF, Atreya R. Endocytoscopy allows accurate in vivo differentiation of mucosal inflammatory cells in IBD: a pilot study. Inflamm Bowel Dis. 2013 Feb;19(2):356-62.

85.   Teichgräber U, Atreya I, Atreya R, Schwab M, Neurath MF. Infliximab treatment induces levels of the active azathioprine metabolite TGTP in Crohn's disease. Inflamm Bowel Dis. 2013 Mar-Apr;19(4):E54-5.

86.   Neumann H, Vieth M, Atreya R, Bernatik T, Mudter J, Neurath MF. Inverted diverticulum or adenomatous lesion? Identification using confocal laser endomicroscopy. Gastrointest Endosc. 2012 May;75(5):1102; discussion 1103.

87.   Neumann H, Wittkopf N, Atreya R, Becker C, Vieth M, Neurath MF. Advanced endoscopic imaging: from the top of the fold to the single bacterium. Gastrointest Endosc. 2012 Jun;75(6):1268-9.

88.   Hundorfean G, Agaimy A, Atreya R, Mudter J, Neurath MF, Neumann H. Confocal laser endomicroscopy for characterization of Crohn's disease-associated duodenitis. Endoscopy. 2012;44 Suppl 2 UCTN:E80.

89.   Hundorfean G, Atreya R, Agaimy A, Heinzerling L, Kämpgen E, Schuler G, Neurath MF. Fluorescein-guided confocal laser endomicroscopy for the detection of ipilimumab-induced colitis. Endoscopy. 2012;44 Suppl 2 UCTN:E78-9.

90.   Neumann H, Vieth M, Atreya R, Grauer M, Siebler J, Bernatik T, Neurath MF, Mudter J. Assessment of Crohn's disease activity by confocal laser endomicroscopy. Inflamm Bowel Dis. 2012 Dec;18(12):2261-9.

91.   Neumann H, Mönkemüller K, Günther C, Atreya R, Vieth M, Neurath MF. Advanced  endoscopic imaging for diagnosis of Crohn's disease. Gastroenterol Res Pract. 2012;2012:301541.

92.   Atreya R, Zimmer M, Bartsch B, Waldner MJ, Atreya I, Neumann H, Hildner K, Hoffman A, Kiesslich R, Rink AD, Rau TT, Rose-John S, Kessler H, Schmidt J, Neurath MF. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages. Gastroenterology. 2011 Dec;141(6):2026-38.

93.   Neumann H, Vieth M, Atreya R, Neurath MF, Mudter J. Prospective evaluation of the learning curve of confocal laser endomicroscopy in patients with IBD. Histol  Histopathol. 2011 Jul;26(7):867-72.

94.   Neumann H, Fuchs FS, Vieth M, Atreya R, Siebler J, Kiesslich R, Neurath MF. Review article: in vivo imaging by endocytoscopy. Aliment Pharmacol Ther. 2011 Jun;33(11):1183-93.

95.   Neumann H, Vieth M, Atreya R, Mudter J, Neurath MF. First description of eosinophilic esophagitis using confocal laser endomicroscopy (with video). Endoscopy. 2011;43 Suppl 2 UCTN:E66.

96.   Waldner MJ, Wirtz S, Jefremow A, Warntjen M, Neufert C, Atreya R, Becker C, Weigmann B, Vieth M, Rose-John S, Neurath MF. VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J Exp Med. 2010 Dec  20;207(13):2855-68.

97.   Atreya R, Waldner MJ, Neurath MF. Molecular imaging: interaction between basic and clinical science. Gastroenterol Clin North Am. 2010 Dec;39(4):911-22.

98.   Holtmann MH, Barreiros AP, Mudter J, Atreya R, Galle PR, Terkamp C, Gebel M.  [Ultrasound education by simulator training--analysis of the largest simulator-based training in Germany]. Z Gastroenterol. 2010 Nov;48(11):1279-84.

99.   Atreya R, Neurath MF. Chemokines in inflammatory bowel diseases. Dig Dis. 2010;28(3):386-94. Atreya R, Neurath MF. Inflammation, peptides and biological therapy. Dig Dis. 2009;27 Suppl 1:42-7.

100.  Atreya R, Neurath MF. New therapeutic strategies for treatment of inflammatory bowel disease. Mucosal Immunol. 2008 May;1(3):175-82.

101.  Mudter J, Amoussina L, Schenk M, Yu J, Brüstle A, Weigmann B, Atreya R, Wirtz S, Becker C, Hoffman A, Atreya I, Biesterfeld S, Galle PR, Lehr HA, Rose-John S, Mueller C, Lohoff M, Neurath MF. The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. J Clin Invest. 2008 Jul;118(7):2415-26.

102.  Atreya I, Atreya R, Neurath MF. NF-kappaB in inflammatory bowel disease. J Intern Med. 2008 Jun;263(6):591-6.

103.  Atreya R, Neurath MF. Signaling molecules: the pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer. Curr Drug Targets. 2008 May;9(5):369-74.

104.  Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath MF. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis. 2007 Nov;13(11):1365-8.

105.  Atreya R, Atreya I, Neurath MF. Novel signal transduction pathways: analysis of STAT-3 and Rac-1 signaling in inflammatory bowel disease. Ann N Y Acad Sci. 2006 Aug;1072:98-113.

106.  Atreya R, Neurath MF. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol. 2005 Jun;28(3):187-96.

107.  Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S,  Becker C, Atreya R, Mudter J, Hildner K, Bartsch B, Holtmann M, Blumberg R, Walczak H, Iven H, Galle PR, Ahmadian MR, Neurath MF. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003 Apr;111(8):1133-45.

108.  Finotto S, De Sanctis GT, Lehr HA, Herz U, Buerke M, Schipp M, Bartsch B, Atreya R, Schmitt E, Galle PR, Renz H, Neurath MF. Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J Exp Med. 2001 Jun 4;193(11):1247-60.

109.  Jostock T, Müllberg J, Ozbek S, Atreya R, Blinn G, Voltz N, Fischer M, Neurath MF, Rose-John S. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem. 2001 Jan;268(1):160-7.

110.  Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schürmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence  in crohn disease and experimental colitis in vivo. Nat Med. 2000 May;6(5):583-8.  Erratum in: Nat Med. 2010 Nov;16(11):1341.

Bücher und Buchkapitel

Atreya R.
Pouchitis.
In: Kucharzik T, Rijcken, E, Bettenworth D, Senninger N (Eds.): Therapie chronisch entzündlicher Darmerkrankungen. De Gruyter, 2018.

Atreya R, Keiner D. Chronisch entzündliche Darmerkrankungen-Krankheitsbild und Therapieoptionen.
In: Schriftenreihe der Bayerischen Landesapothekerkammer. Govi, 2017.  

Atreya R, Billmeier U, Rath T, Neumann H, Neurath MF.
Binding of Membrane-Bound TNF
In: Rogler G, Herfarth H, Hibi T, Nielsen OH (Eds.): Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Karger, 2015.

Atreya R, Neurath MF.
The normal intestinal mucosa: a state of “controlled” inflammation.
In: Targan SR, Shanahan F, Karp LC (Eds.): Inflammatory Bowel Disease: Translating Basic Science into Clinical Practice. Wiley-Blackwell, 2010.

Atreya R, Neurath MF.
The Role of the JAK/STAT Pathway in Inflammatory Bowel Diseases.
In: Stephanou A (Ed.): JAK-STAT Pathway in Disease. Landes Bioscience, 2009.

Atreya R, Neurath MF.
Future Trends in Confocal Laser Endomicroscopy: Improved Imaging Quality and Immunoendoscopy.
In: Kiesslich R, Galle PR, Neurath MF (Eds.): Atlas of Endomicroscopy. Springer Medizin Verlag Heidelberg, 2008.  

Neurath MF, Becker C, Mudter J, Atreya R, Hildner K, Wirtz S, Finotto S.
New cytokines and their impact in mucosal pathogenesis.
Andus T (Ed.): Cytokines and cell homeostasis in the gastrointestinal tract. Kluwer Academic Publishers, 2000.

Neurath MF, Becker C, Mudter J, Atreya R, Hildner K, Wirtz S, Finotto S.
Immunotherapeutic approaches in inflammatory bowel diseases.
Rogler G (Ed.): IBD at the end of its first century. Kluwer Academic Publishers, 2000.

Preise

2017      Oral Free-Paper Price, United European Gastroenterology Federation

2017      Digital Oral Presentation Award, European Crohn´s and Colitis Organization

2015      Rising Star Award, United European Gastroenterology Federation

2015      Paul Ehrlich- und Ludwig Darmstädter-Nachwuchspreis, Paul Ehrlich-Stiftung

2014      Theodor-Frerichs-Preis, Deutsche Gesellschaft für Innere Medizin (DGIM)
               
2012      „Spitzen-Abstract“, Gesellschaft für Gastroenterologie in Bayern  (GFGB)

2012      Oral Free-Paper Price, United European Gastroenterology Federation (UEGW)

2011      Oral Free-Paper Price, United European Gastroenterology Federation (UEGW)

2009      Ludwig-Demling-Forschungspreis, Deutsche Morbus Crohn/ Colitis ulcerosa Vereinigung e.V. (DCCV)

2004      Förderpreis, Boehringer Ingelheim Stiftung

2000      3. Preis der freien Vorträge, Deutsche Gesellschaft für Innere Medizin (DGIM)

1999      Förderungsstipendium des Fachbereichs Medizin, Johannes Gutenberg-Universität Mainz